NEW YORK, April 22, 2020 (GLOBE NEWSWIRE) -- via NetworkNewsAudio — Predictive Oncology (NASDAQ: POAI) today announces that Company director and CEO Dr. Carl Schwartz, in an interview with NetworkNewsWire (NNW), discussed the Predictive Oncology’s distinctive business model and significant changes management is making to position the Company for the future.
The broadcast of the exclusive audio interview produced by NNW, a financial news and content distribution company and one of 40+ brands in the InvestorBrandNetwork (IBN), can be heard at http://nnw.fm/o7Ysq.
The interview discusses the evolution of Predictive Oncology. “As we moved forward, we changed our focus to artificial intelligence through our wholly owned subsidiary Helomics,” Schwartz said. Another key change came with the acquisition of a second wholly owned subsidiary, TumorGenesis. Continuing this growth strategy, the Company is now is in the process of acquiring two biological firms: Soluble Therapeutics and BioDtech.
“Predictive’s major asset is its Helomics subsidiary and its proprietary database of over 150,000 cancer tumors covering over 137 types of cancers, with over 30,000 tumors related to ovarian cancer, which is sort of our specialty. In fact, this is the largest inventory of its kind in the world,” stated Schwartz.
Schwartz further explained that this phenomenal collection was amassed over the last two decades by physicians sending in cancerous tumors to be tested with the known therapies of the time. “The results of these tests were in turn sent back to the referring physicians to be used as a guide or a reference as desired for treatment of the evaluated tumor,” he said. “And the evaluated tumor was placed back in the physician’s therapy inventory. That’s how we amassed all these tumors.”
The Company’s ultimate goal for Helomics is to replicate the path taken by Foundation Medicine and its relationship with Roche Pharmaceutical in obtaining funds for research.
“We ultimately need to prove that we’re able to sequence, which is genetically profile our tumors, and do what is called a ‘reach back,’ or examination of what eventually happened to these patients over an extended period of time,” Schwartz said. “I want to strongly emphasize that Helomics is the only company with the ability to do this ‘reach back’ at this time because only we have a patient history. I want to make sure I emphasize that we’re the only company that has this history.”
During the interview, Schwartz also pointed out other key components of Predictive Oncology’s strategic plan moving forward, including its CancerQuest 2020 project conducted in partnership with UPMC Magee, an agreement with Interface Diagnostics to do a thyroid study utilizing POAI’s AI model, and other projects involved precision medicine trials and prostate cancer.
“This should be enough information to demonstrate our ability to validate our process,” Schwartz said. “We will then go to pharma industry for major funding. And we’re pretty excited about this. We think we’re going to finally get to the top of the heap here very shortly.”
Listen to the full interview with Predictive Oncology’s Carl Schwartz at http://nnw.fm/o7Ysq
About Predictive Oncology Inc.
Predictive Oncology (NASDAQ: POAI) operates through three segments (Domestic, International and other), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.
About NetworkNewsAudio (NNA)
NetworkNewsAudio (“NNA”) allows you to sit back and listen to market updates, CEO interviews and a company AudioPressRelease (“APR”). These audio clips provide snapshots of position, opportunity and momentum. NNA can assist your company by cutting through the overload of information in today's market. NNA brings its Client Partners unparalleled visibility, recognition and brand awareness. NNA is just one site within our sizable family of 40+ brands within the InvestorBrandNetwork (“IBN”). IBN is a comprehensive provider of news and original articles; we aggregate and syndicate this content for much bigger impact. IBN also adds Press Release Enhancement and a full array of social media communication solutions and has amassed a collective audience that includes millions of social media followers. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, IBN has the unparalleled ability to reach a wide audience comprising investors, consumers, journalists and the general public with an ever-growing distribution network of 5,000+ key syndication outlets across the nation.
IBN is where news, content and information converge.
For more information, visit: www.NetworkNewsAudio.com
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.
Los Angeles, California
Source: Predictive Oncology